Ryan Charles S. 4

What Happened Ryan Charles, President of Quince Therapeutics (QNCX), was granted a derivative award covering 200,000 shares on January 23, 2026. The filing records the acquisition price as $0.00 and reports the award as a derivative (i.e., option/award), not an open-market purchase or sale. This is a compensation grant rather than a sale or personal cash purchase.

Key Details

• Transaction date: 2026-01-23 (reported and filed on 2026-01-23).
• Transaction type: Grant / award (derivative); 200,000 shares; price shown as $0.00; total reported value $0 in filing.
• Shares owned after transaction: Not reported in the provided filing.
• Vesting (footnote): Shares vest in equal monthly installments of 1/48th beginning on the grant date (1/48th vests on the date of grant) with remaining monthly vesting so that all shares fully vest on December 1, 2029.
• Filing timeliness: Filing date matches the report date; no late filing indicated in the provided record.

Context This is a standard equity compensation grant to an executive. Because it is a derivative award with a multi-year monthly vesting schedule, the recipient does not receive (or control) all shares immediately — full vesting occurs by Dec 1, 2029. Such grants are common in executive pay packages; they are not direct market purchases and should be interpreted as part of compensation rather than an immediate bullish purchase signal.